BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Budesonide (Entocort EC) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Budesonide (Entocort EC)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05405387-9595@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Budesonide (Entocort EC): Phase 2 readout est. (NCT05405387)
DESCRIPTION:Budesonide (Entocort EC)\, phase 2.\nStudy: Impact of Budesonid
 e on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Under
 going Autologous Stem Cell Transplant\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/budesonide-
 entocort-ec#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05405387
URL:https://assetmemo.bio/drug/budesonide-entocort-ec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
